• 首页
  • 期刊介绍
  • 编委会
  • 投稿指南
  • 期刊订阅
  • 广告合作
  • 留言板
  • 联系我们
  • English
葛沐子,伍一军.伊维菌素用于新型冠状病毒肺炎防治的研究[J].中国比较医学杂志,2022,32(6):128~136.
伊维菌素用于新型冠状病毒肺炎防治的研究
Can ivermectin be used in the prevention and treatment of COVID-19? — A review study
投稿时间:2021-12-10  
DOI:10. 3969 / j.issn.1671-7856. 2022. 06. 020
中文关键词:  伊维菌素  新型冠状病毒  新型冠状病毒肺炎  联合用药  预防  治疗
英文关键词:ivermectin  SARS-CoV-2  COVID-19  drug combination  prevention  therapy
基金项目:
作者单位E-mail
葛沐子 中国科学院动物研究所分子毒理学实验室,北京 100101 gmz8k8k@ 126. com 
伍一军 中国科学院动物研究所分子毒理学实验室,北京 100101 wuyj@ ioz. ac. cn 
摘要点击次数: 336
全文下载次数: 154
中文摘要:
      新型冠状病毒肺炎(COVID-19)是由新型冠状病毒(SARS-CoV-2)感染引发的高传染性和高感染率的疾病,导致全球数百万人死亡。 除了利用疫苗进行预防外,研发能够治疗或缓解新型冠状病毒肺炎的有效药物极为迫切。但病毒的高突变率导致目前研发的疫苗和药物有效性降低甚至完全无效。大环内酯类化合物伊维菌素(ivermectin)是一种常用的抗寄生虫药物,但它具有包括抗炎、抗病毒、抗肿瘤在内的多种药理作用。 近期研究表明,伊维菌素有抑制 SARS-CoV-2 感染及缓解症状的作用。本文基于对伊维菌素和 SARS-CoV-2 互作的生物信息学 分析、实验室细胞模型验证和动物实验研究结果以及流行病学数据研读,分析伊维菌素用于抗 SARS-CoV-2 感染的可行性与改进策略,认为有必要深入开展相关动物实验研究和临床应用疗效评价,并考虑采用联合用药策略提高其防治效果。
英文摘要:
      Coronavirus disease 2019 (COVID-19) is an extremely infectious disease with a high infection rate that is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease, which can cause severe respiratory symptoms and lung damage, has killed millions of people worldwide since the COVID-19 pandemic began. In addition to the necessity for vaccine prevention to control this pandemic, there is also an extremely urgent need to develop drugs that can effectively inhibit SARS-CoV-2 infection or treat symptomatic COVID-19. However, the high mutation rate of the SARS-CoV-2 virus has led to frequent failures of the vaccines and drugs that have been developed to date. Ivermectin, a macrolide compound, is a commonly used anti-parasitic drug, and it also has a variety of pharmacological effects, including anti-inflammatory, anti-viral, and anti-tumor effects. Recent studies have shown that ivermectin may inhibit SARS-CoV-2 infection or relieve COVID-19 symptoms. The feasibility of an improved strategy of ivermectin use against SARS-CoV-2 infection, based on a bioinformatics analysis of the interaction between ivermectin and SARS-CoV-2 receptors, cell model validation, animal infection model studies, and epidemiological data, is discussed in this review article. The existing research data are insufficient, so it remains necessary to perform a clinical efficacy evaluation for determining whether ivermectin can be used clinically for the treatment of COVID-19 caused by SARS-CoV-2 infection. In addition, a strategy of drug combination could be adopted to improve the effect of ivermectin on the inhibition of SARS-CoV-2 and the treatment of COVID-19.
查看全文  查看/发表评论  下载PDF阅读器
关闭
您是第 6102857 位访问者
版权所有:中国实验动物学会 主管单位:中国科学技术协会 主办单位:中国实验动物学会 中国医学科学院医学实验动物研究所
地  址: 北京市朝阳区潘家园南里5号 邮编:100021 电话:010-67779337 E-mail:bjb@cnilas.org
本系统由北京勤云科技发展有限公司设计
微信关注二维码